Navigation Links
Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/6/2012

SAN DIEGO, Jan. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 30th Annual J. P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California.   

The corporate presentation will review the Company accomplishments in 2011, as well as outline the corporate plans for 2012 and beyond.

Specifically, the Company will discuss the recent very productive Type C meeting that was held with the FDA on elagolix for endometriosis, one of the outcomes of which was the decision to file a Special Protocol Assessment (SPA) with the FDA. The expected NDA filing of elagolix for the treatment of endometriosis is in 2015.

Additionally, the presentation will cover the Company's VMAT2 program for movement disorders, including the status of the current Phase II study assessing the impact of NBI-98854 in patients with tardive dyskinesia. This study, which began in the fall of 2011, has recently completed enrollment and will report top-line data in the first quarter of 2012.  The Company also recently received a notification of allowable claims for its NBI-98854 European Patent Application from the European Patent Office, and has begun planning for larger Phase IIb trials, to be launched in mid-2012, for up to three months of continuous treatment with NBI-98854.

 

The live presentation takes place on Thursday, January 12, 2012 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  A copy of the presentation materials will be filed with the Securities and Exchange Commission on or before Monday, January 9, 2012.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
6. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
7. Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids
8. Neurocrine Biosciences To Present at the Stifel Nicolaus 2011 Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
10. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
11. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):